Learn about PERJETA-based treatment before surgery

Treatment before breast cancer surgery (also known as neoadjuvant treatment) may be an option for HER2-positive (HER2+) early breast cancer. Doctors may choose neoadjuvant treatment for early breast cancer to shrink a tumor.

PERJETA is part of an FDA-approved neoadjuvant treatment regimen for HER2+ early breast cancer, along with Herceptin® (trastuzumab) and docetaxel. Talk to your doctor to determine if treatment before breast cancer surgery may be right for you.

Why consider treatment before surgery?
 

Learn why your treatment plan may include treatment before surgery.

 

How PERJETA-based treatment is given
 

PERJETA-based treatment can be given before surgery for HER2+ early breast cancer.
 

PERJETA for HER2+ early breast cancer before surgery

See the potential benefits and risks associated with PERJETA-based treatment for HER2+ early breast cancer.

Talking with your doctor

 

Some tips on how to get the most out of your doctor’s appointments.